On Thursday, OpenAI unveiled a new artificial intelligence model that boasts enhanced expertise in biology and scientific research, marking the company’s broader engagement in the life sciences sector.

The model, named GPT-Rosalind in honor of the renowned 20th-century British scientist Rosalind Franklin, aims to assist in various domains such as biochemistry, drug development, and translational medicine.

There has been a growing demand for AI-driven solutions to expedite drug discovery and research among pharmaceutical corporations, academic institutions, and biotech companies.

According to a blog post by OpenAI, “This model is intended to facilitate researchers in speeding up the initial phases of discovery by aiding in evidence synthesis, hypothesis formulation, experimental design, and other complex research tasks.”

Researchers will have the capability to access databases, review the latest scientific literature, utilize additional scientific resources, and propose new experimental endeavors while using this model, as indicated by OpenAI in a recent press briefing. The GPT-Rosalind model is built upon OpenAI’s latest internal architectures.

This new model is currently accessible as a research preview in ChatGPT, Codex, and through the API for eligible users via OpenAI’s trusted access deployment framework. Additionally, the company is introducing a complimentary Life Sciences research plugin for Codex, which links scientists to more than 50 scientific tools and databases.

OpenAI has stated that it is collaborating with clients such as Amgen, Moderna, and Thermo Fisher Scientific, among others, to integrate GPT-Rosalind into various workflows.

Earlier this week, OpenAI, the developer of the widely-used ChatGPT chatbot, also announced the launch of GPT-5.4-Cyber, a specialized version of its latest flagship model tailored for defensive cybersecurity purposes, in response to the announcement of Anthropic’s frontier AI model, Mythos.